Algorithms for the automated selection of fragment-like molecules using single-point surface plasmon resonance measurements

Analytical Biochemistry

Volumn 402, Issue 2, 2010, Pages 179-184

  Kreatsoulas, Constantine ^a   Narayan, Kartik ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Compound ranking; Fragment based lead discovery; Hit identification; Hit selection; Surface plasmon resonance

Indexed keywords

BINDERS; PLASMONS; RESONANCE;

ANOMALOUS BEHAVIOR; AUTOMATED SELECTION; COMPOUND RANKING; DRUG DISCOVERY; FRAGMENT-BASED LEAD DISCOVERY; HIT SELECTION; LARGE VOLUMES; NEW APPROACHES;

SURFACE PLASMON RESONANCE;

ARTICLE; AUTOMATION; BINDING AFFINITY; CONTROLLED STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOLECULAR INTERACTION; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SURFACE PLASMON RESONANCE; VALIDATION PROCESS;

EID: 77953082709     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.03.042     Document Type: Article

References (17)

1. Mayr L.M., Bojanic D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 2009, 9:580-588.
2. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
3. Schulz M.N., Hubbard R.E. Recent progress in fragment-based lead discovery. Curr. Opin. Pharmacol. 2009, 9:615-621.
4. Schuffenhauer A., Ruedisser S., Marzinzik A.L., Jahnke W., Blommers M., Selzer P., Jacoby E. Library design for fragment based screening. Curr. Top. Med. Chem. 2005, 5:751-762.
5. Congreve M., Carr R., Murray C., Jhoti H. A " rule of three" for fragment-based lead discovery?. Drug Discov. Today 2003, 8:876-877.
6. Hajduk P.J. Fragment-based drug design: how big is too big?. J. Med. Chem. 2006, 49:6972-6976.
7. Reitz A.B., Smith G.R., Tounge B.A., Reynolds C.H. Hit triage using efficiency indices after screening of compound libraries in drug discovery. Curr. Top. Med. Chem. 2009, 9:1718-1724.
8. Hann M.M., Leach A.R., Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41:856-864.
9. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
10. Verdonk M.L., Hartshorn M.J. Structure-guided fragment screening for lead discovery. Curr. Opin. Drug Discov. Dev. 2004, 7:404-410.
11. Wyatt P.G., Woodhead A.J., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Davis D.J., Devine L.A., Early T.R., Feltell R.E., Lewis E.J., McMenamin R.L., Navarro E.F., O'Brien M.A., O'Reilly M., Reule M., Saxty G., Seavers L.C., Smith D.M., Squires M.S., Trewartha G., Walker M.T., Woolford A.J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J. Med. Chem. 2008, 51:4986-4999.
12. Neumann T., Junker H.D., Schmidt K., Sekul R. SPR-based fragment screening: advantages and applications. Curr. Top. Med. Chem. 2007, 7:1630-1642.
13. Perspicace S., Banner D., Benz J., Muller F., Schlatter D., Huber W. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen. 2009, 14:337-349.
14. Danielson U.H. Fragment library screening and lead characterization using SPR biosensors. Curr. Top. Med. Chem. 2009, 9:1725-1735.
15. Giannetti A.M., Koch B.D., Browner M.F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem. 2008, 51:574-580.
16. Truchon J.F., Bayly C.I. Evaluating virtual screening methods: Good and bad metrics for the " early recognition" problem. J. Chem. Inf. Model. 2007, 47:488-508.
17. Sheridan R.P., Singh S.B., Fluder E.M., Kearsley S.K. Protocols for bridging the peptide to nonpeptide gap in topological similarity searches. J. Chem. Inf. Comput. Sci. 2001, 41:1395-1406.